Tugce Telli

Nuclear medicine physician, clinician scientist currently in Germany

[Michael Hofman @DrMHofman]

#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25

First prospective trial of Terbium-161 in any tumour type
🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq)
🟣 Very few side effects: 1 grade 3 lymphopenia, 1 grade 3 pain exacerbation. No grade 4. No dose delays.
🟣 PSA >90% response in 40%
🟣 Completed >6 months ahead of schedule

https://t.co/AQdZm6PKE7 in press @TheLancetOncol

🟣 Thanks to @ButeauJames @AzadOncology @pj_physics @LouiseKostos @MHaskali
🟣 Funding from @PCF_Science @pros_tic @PeterMacCC
🟣 Terbium-161 PSMA supplied from @Isotopia_Global

[Yüksel Ürün @DrYukselUrun]

FDA expands Pluvicto use in PSMA+ mCRPC before chemo.
@US_FDA @APCCC_Lugano @PCFnews @OncoAlert

[Michael Hofman @DrMHofman]

Congrats to Lisa Gudenkauf @MoffittNews for presenting @ASCO #GU25

Pleased to part of this research led by @BrianDGonzalez developing a new tool for recording patient-reported outcomes when receiving PSMA theranostics

Covered by @urotoday : https://t.co/v4rFBhZPQJ

Abstract here: https://t.co/vFWMvaEujR

And our @JournalofNucMed manuscript:
https://t.co/VulmLxKYkl

[Michael Hofman @DrMHofman]

New GA-68 GPC3 peptide first-in-human series:
https://t.co/D1tVZVDUNv @JournalofNucMed

19 patients with hepatocellular carcinoma: mean SUVmax 20 (range 3 - 95)

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on @TheLancetOncol

https://t.co/CMBBfhGjSH

This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against established clinical nomograms for prostate cancer, focusing on overall survival.

Data from 2,414 patients with #ProstateCancer from hospitals in Germany🇩🇪 were analyzed, with follow-up data linked to mortality records. Using Cox regression models, the researchers developed quantitative and visual PPP nomograms, which were validated both internally and externally

The PPP nomograms showed superior or comparable predictive accuracy for overall survival compared to traditional risk scores, like STARCAP, EAU, and NCCN, in different stages of prostate cancer. Further validation and refinement are ongoing.

@ViktorGruenwald
@JensKleesiek
@TugceTelli_
@ClaudiaKesch
@ProfKHerrmann
@MatthiasEiber
@SHoberueck
@Dr_K_Rahbar
@stangandreas
@ProfHadaschik

[Baris Turkbey MD @radiolobt]

Standardized template for clinical reporting of PSMA PET/CT scans
https://t.co/GaJPC1RAZz
🔵Clear communication of imaging study results is just as crucial as performing and interpreting them
👍A valuable recommendation article on standardized reporting of PSMA PET/CT scans to enhance collaboration between imaging doctors and referring physicians
🏅Congratulations to @ShadiEsfahani and all co-authors
#PSMAPETCT #MedicalImaging #Radiology #NuclearMedicine #molecularimaging #prostatecancer

[Emre Yekedüz @yekeduz_emre]

⚠️💥Data from 2414 prostate cancer patients across multiple hospitals to compare PSMA-PET by PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) (PPP) stage with established clinical nomograms.

⚛️PPP nomograms showed superior prediction accuracy for overall survival compared to STARCAP, EAU, and NCCN risk scores.

https://t.co/9K8vQdfWpz

@OncoAlert @TheLancetOncol @ViktorGruenwald @ecguTelli

#prostate #Cancer #MedTwitter

[Ken Herrmann @ProfKHerrmann]

Standardized PSMA PET using PROMISE criteria accurately stratify high-risk and low-risk groups for OS in early and late stages of prostate cancer. Great effort led by Wolfgang Fendler. https://t.co/bGUXK7kJub @JensKleesiek @ecguTelli @ClaudiaKesch @MatthiasEiber @ProfHadaschik

[Tugce Telli @TugceTelli_]

#YasayıGeriÇek

[KAFA Dergisi @kafadergisi]

Bir köpeği sevmekle başlayacak her şey 🐾

[Baris Turkbey MD @radiolobt]

Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database https://t.co/oGe7a1EJPK
#prostatecancer #CancerResearch #MolecularImaging

[Update in Nuclear Medicine @update_in_nm]

The Homunculus for unspecific bone uptake (UBU) seen on PSMA PET imaging, for more details https://t.co/y9Tp2SnqUV #prostatecancer #psma #psmapetct

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in @EurUrolOncol 👉 Expert guidance (by modified Delphi panel method) on management of AEs in patients with #prostatecancer receiving combination PARPi + ARPI (NHT) treatment 👉link: https://t.co/ydGn1REZ9L @urotoday @PCF_Science @OncoAlert @ZEROCancer

[Tugce Telli @TugceTelli_]

✅ We should carefully consider this in PET/CT scans of oncology patients
🧨under anti-hormonal therapy
🧨w. monoclonal gammopathies
🧨w. lymphoma
🧨after bone marrow transplantation
🧨chronic corticosteroid therapy
🧨long-term survivors
🧨GI tumors
🧨after total thyroidectomy

[Sameer Raniga @samrad77]

L1 vertebral body attenuation, as measured on the sagittal plane of a CT abdomen, with a value less than 150 HU, highly suggests osteoporosis. Recommend the DEXA test for bone mineral densitometry!

32-year-old with a CT attenuation of 110 HU and a compression fracture of T12.

[Yüksel Ürün @DrYukselUrun]

PSMAfore Trial Update by K. Fizazi @GustaveRoussy
⭕️177Lu-PSMA-617 delayed worsening in pain and health-related quality of life (HRQoL) compared to changing ARPI in taxane-naïve mCRPC patients.
⭕️Adverse event rates were lower with 177Lu-PSMA-617. #ProstateCancer #ClinicalTrials @jacobadashek @twooncdocs @devikadasMD @PCFnews @OncBrothers @anavmanana @oncoalert #ASCO24 @ASCO @Larvol

[DAG @DrAGhanim]

DDX .......
CT Spinal Bone Pathology ......

[ASCO @ASCO]

ASCO-@IntegrativeOnc guideline update now available: Management of Fatigue in Adult Survivors of Cancer ➡️ https://t.co/t5zgJZ2KZY #PallOnc #SurvOnc

[Jeremie Calais @CalaisJeremie]

We can do better than a fixed set of 6 cycles of LuPSMA at a 6-week time interval !
Great multicenter data of >100 patients from Germany published in @JournalofNucMed.
Happy to open @UCLA with @Novartis the phase 2 trials FLEX-MRT and RE-LuPSMA.
https://t.co/mOr7UHE2xi

[Dr. Longissimus @DrLongissimus]

Beautiful picture of the aurora borealis from my office

[Tugce Telli @TugceTelli_]

@MdNukedoc Thanks🙏🏾

[Tugce Telli @TugceTelli_]

I am really happy to be one of the first authors of this article in @JournalofNucMed and have the oppurtunity to collect and analyse the data of patients received > 6 cycles of LuPSMA from different NM centers in Germany. Higlights:
🎯Favorable safety
🎯Maintained response